Az IgA-nephropathia terápiája

Translated title of the contribution: Treatment of IgA nephropathy

Tibor Vas, Tibor Kovács, István Késöi, Balázs Sági, Péter Degrell, I. Wittmann, J. Nagy

Research output: Contribution to journalArticle

Abstract

IgA nephropathy is the most common primary glomerulonephritis worldwide. The clinical spectrum covers a wide range of features from minor urinary abnormalities (asymptomatic hematuria and mild proteinuria with normal renal function) to acute and chronic renal insufficiency. Ideally, the goal of treatment would be to correct any defects in IgA1 glycosylation and to modify mesangial deposition or removal of IgA1 deposits. There are only a few randomized controlled trials in IgA nephropathy; for this reason most treatment options are largely based on expert opinion. Authors discuss therapeutic options of different clinical pictures and the optimized renoprotective treatment of all IgA nephropathy patients.

Original languageHungarian
Pages (from-to)2039-2046
Number of pages8
JournalOrvosi Hetilap
Volume152
Issue number51
DOIs
Publication statusPublished - Dec 1 2011

Fingerprint

Immunoglobulin A
Therapeutics
Expert Testimony
Hematuria
Glomerulonephritis
Chronic Renal Insufficiency
Glycosylation
Proteinuria
Acute Kidney Injury
Randomized Controlled Trials
Kidney

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vas, T., Kovács, T., Késöi, I., Sági, B., Degrell, P., Wittmann, I., & Nagy, J. (2011). Az IgA-nephropathia terápiája. Orvosi Hetilap, 152(51), 2039-2046. https://doi.org/10.1556/OH.2011.29278

Az IgA-nephropathia terápiája. / Vas, Tibor; Kovács, Tibor; Késöi, István; Sági, Balázs; Degrell, Péter; Wittmann, I.; Nagy, J.

In: Orvosi Hetilap, Vol. 152, No. 51, 01.12.2011, p. 2039-2046.

Research output: Contribution to journalArticle

Vas, T, Kovács, T, Késöi, I, Sági, B, Degrell, P, Wittmann, I & Nagy, J 2011, 'Az IgA-nephropathia terápiája', Orvosi Hetilap, vol. 152, no. 51, pp. 2039-2046. https://doi.org/10.1556/OH.2011.29278
Vas T, Kovács T, Késöi I, Sági B, Degrell P, Wittmann I et al. Az IgA-nephropathia terápiája. Orvosi Hetilap. 2011 Dec 1;152(51):2039-2046. https://doi.org/10.1556/OH.2011.29278
Vas, Tibor ; Kovács, Tibor ; Késöi, István ; Sági, Balázs ; Degrell, Péter ; Wittmann, I. ; Nagy, J. / Az IgA-nephropathia terápiája. In: Orvosi Hetilap. 2011 ; Vol. 152, No. 51. pp. 2039-2046.
@article{ff5041f3a8174b4996b9c0e9aba7b849,
title = "Az IgA-nephropathia ter{\'a}pi{\'a}ja",
abstract = "IgA nephropathy is the most common primary glomerulonephritis worldwide. The clinical spectrum covers a wide range of features from minor urinary abnormalities (asymptomatic hematuria and mild proteinuria with normal renal function) to acute and chronic renal insufficiency. Ideally, the goal of treatment would be to correct any defects in IgA1 glycosylation and to modify mesangial deposition or removal of IgA1 deposits. There are only a few randomized controlled trials in IgA nephropathy; for this reason most treatment options are largely based on expert opinion. Authors discuss therapeutic options of different clinical pictures and the optimized renoprotective treatment of all IgA nephropathy patients.",
keywords = "galactose-deficient IgA, IgA nephropathy, IgA subclass1, renoprotective treatment",
author = "Tibor Vas and Tibor Kov{\'a}cs and Istv{\'a}n K{\'e}s{\"o}i and Bal{\'a}zs S{\'a}gi and P{\'e}ter Degrell and I. Wittmann and J. Nagy",
year = "2011",
month = "12",
day = "1",
doi = "10.1556/OH.2011.29278",
language = "Hungarian",
volume = "152",
pages = "2039--2046",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "51",

}

TY - JOUR

T1 - Az IgA-nephropathia terápiája

AU - Vas, Tibor

AU - Kovács, Tibor

AU - Késöi, István

AU - Sági, Balázs

AU - Degrell, Péter

AU - Wittmann, I.

AU - Nagy, J.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - IgA nephropathy is the most common primary glomerulonephritis worldwide. The clinical spectrum covers a wide range of features from minor urinary abnormalities (asymptomatic hematuria and mild proteinuria with normal renal function) to acute and chronic renal insufficiency. Ideally, the goal of treatment would be to correct any defects in IgA1 glycosylation and to modify mesangial deposition or removal of IgA1 deposits. There are only a few randomized controlled trials in IgA nephropathy; for this reason most treatment options are largely based on expert opinion. Authors discuss therapeutic options of different clinical pictures and the optimized renoprotective treatment of all IgA nephropathy patients.

AB - IgA nephropathy is the most common primary glomerulonephritis worldwide. The clinical spectrum covers a wide range of features from minor urinary abnormalities (asymptomatic hematuria and mild proteinuria with normal renal function) to acute and chronic renal insufficiency. Ideally, the goal of treatment would be to correct any defects in IgA1 glycosylation and to modify mesangial deposition or removal of IgA1 deposits. There are only a few randomized controlled trials in IgA nephropathy; for this reason most treatment options are largely based on expert opinion. Authors discuss therapeutic options of different clinical pictures and the optimized renoprotective treatment of all IgA nephropathy patients.

KW - galactose-deficient IgA

KW - IgA nephropathy

KW - IgA subclass1

KW - renoprotective treatment

UR - http://www.scopus.com/inward/record.url?scp=82955243814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82955243814&partnerID=8YFLogxK

U2 - 10.1556/OH.2011.29278

DO - 10.1556/OH.2011.29278

M3 - Article

VL - 152

SP - 2039

EP - 2046

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 51

ER -